Article Text

Download PDFPDF
Reconsidering the revised amyotrophic lateral sclerosis functional rating scale for ALS clinical trials
  1. Adriaan D de Jongh1,
  2. Leonard H van den Berg1,
  3. Ruben P A van Eijk1,2
  1. 1Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
  2. 2Biostatistics and Research Support, Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands
  1. Correspondence to Dr Ruben P A van Eijk, Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands; R.P.A.vanEijk-2{at}umcutrecht.nl

Statistics from Altmetric.com

Introduction

Clinical trials in amyotrophic lateral sclerosis (ALS) aim to identify treatments that can slow functional decline or prolong survival time. In the absence of objective biomarkers, questionnaires, such as the ALS Functional Rating Scale (ALSFRS), are used to evaluate treatment effects in clinical trials.1 Although questionnaires are easy to administer and hold prognostic value, they may miss important treatment clues if questions are not selected appropriately. For example, the ALSFRS was originally designed as a 10-item functional score across bulbar, fine and gross motor and respiratory domains. The ALSFRS was revised in 1999 by adding two respiratory items.1 Whether this revision resulted in an improved endpoint is debatable, as the questionnaire’s construct validity may have worsened, resulting in weaker correlations with respiratory function and survival.1 2 Nevertheless, the ultimate, real-world application of the ALSFRS is to serve as efficacy endpoint. Solely assessing validity may not suffice to evaluate whether a revision, or new questionnaire, is more suitable as endpoint. We propose, therefore, to evaluate longitudinal biomarkers and questionnaires, not only in terms of validity, but also in terms of trial design. Ultimately, this strategy may aid the selection of optimal efficacy endpoints for ALS or other neurodegenerative disease clinical trials.

Methods

Individual participant data

We used 12-month data from PRO-ACT to compare the ALSFRS and the ALSFRS-Revised (ALSFRS-R). PRO-ACT contains anonymised data from 23 clinical trials, conducted since 1990.3 Only data from trials that included the ALSFRS-R were used. To make the PRO-ACT data set comparable to common trial populations, we excluded patients with a symptom duration >36 months, vital capacity <60% or who were over 80 years of age.

Outcome measures

ALSFRS and ALSFRS-R total scores were calculated as the sum …

View Full Text

Footnotes

  • Contributors ADdJ, RPAvE and LHvdB designed the study. ADdJ and RPAvE analysed the data and drafted the manuscript. RPAvE and LHvdB critically reviewed the manuscript.

  • Funding This study was supported by the Netherlands ALS Foundation (Project TRICALS-Reactive 2018-66).

  • Competing interests ADdJ and RPAvE report no disclosures. LHvdB reports grants from Netherlands ALS Foundation, the Netherlands Organization for Health Research and Development (Vici scheme), the Netherlands Organization for Health Research and Development (SOPHIA, STRENGTH, ALS-CarE project), funded through the EU Joint Programme – Neurodegenerative Disease Research, JPND), served on the Scientific Advisory Board of Biogen, Cytokinetics, Prinses Beatrix SpierFonds and the Latran Foundation.

  • Patient consent for publication Not required.

  • Ethics approval The PRO-ACT database is institutional review board approved and uses anonymised data. Subjects consented to participate during the individual trials.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.